Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.
She has an MA in business and economic reporting from New York University. You can connect with Laura on LinkedIn or Twitter.
OneOncology’s Clinical Pathways Covers Best Practices for 90% of Patients, Says Dr Ted Arrowsmith
November 13th 2022The disease groups that make up the OneOncology clinical pathways program cover 90% of patients with cancer and develop best practices for treating cancer in the majority of patients, said Edward “Ted” Arrowsmith, MD, MPH, managing partner and director of research, East Tennessee Division, Tennessee Oncology.
Read More
Dr Timothy Murphy: Strong Communication Is Necessary for Practices Stocking Multiple Biosimilars
November 13th 2022With multiple biosimilars approved for a reference product and different payers preferring particular products, communication between the clinical pharmacy team and the managed care team is crucial, said Timothy Murphy, MD, FACP, medical oncologist/hematologist with Rocky Mountain Cancer Centers.
Read More
Dr Davey Daniel Hits the High Points of the OneOncology Annual Conference
November 12th 2022The OneOncology Annual Conference is being held November 11-13 in Nashville, Tennessee, and brings together practice leaders, physicians, and advanced practice providers to discuss the business of oncology and scientific advancements, explained Davey Daniel, MD, chief medical officer of OneOncology.
Read More
Dr Jeffrey Patton on Setting Standards of Care Through OneOncology’s Clinical Pathways Program
November 11th 2022Representatives across 12 disease groups make up a council that sets clinical recommendations for oncology care and those decisions are being pushed out in the electronic medical record for decision support at the point of care, said Jeffrey Patton, MD, CEO, OneOncology, and executive chairman of the board, Tennessee Oncology. Patton will lead off OneOncology's Physician Leadership Conference, which runs November 11-13 in Nashville.
Read More
Rheumatologists Grow More Comfortable With Biosimilars, but Concerns Remain
November 4th 2022Ahead of the big wave of adalimumab biosimilars launching in the US market in 2023, rheumatologists report growing confidence in using biosimilars but remain concerned about their efficacy and economic benefit.
Read More
Dr Timothy Murphy Discusses Successfully Implementing Biosimilars Into Community Cancer Practice
October 28th 2022Having a plan in place to educate providers and the pharmacy team has contributed to the success that Rocky Mountain Cancer Centers (RMCC) has had with rapidly implementing biosimilars, said Timothy Murphy, MD, medical oncologist/hematologist with RMCC.
Read More
Returning to a Humanistic Approach of Preventing Delirium in the ICU
October 18th 2022In the Roger C. Bone Memorial Lecture in Critical Care at CHEST 2022, E. Wesley Ely, MD, MPH, of the Vanderbilt University School of Medicine, highlights the need for humanism in the intensive care unit and how the COVID-19 pandemic destroyed what had been built up.
Read More
Dr Steven Yeh: Xipere’s New Delivery Method Requires Patient, Physician Education
October 18th 2022Patients with uveitis and their physicians may be very familiar with intravitreal injections, but triamcinolone acetonide injectable suspension (Xipere) has a novel delivery method, said Steven Yeh, MD, professor and the Stanley Truhlsen Jr. Chair in Ophthalmology at the Truhlsen Eye Institute, University of Nebraska Medical Center.
Read More
Patients With Uncontrolled Asthma May Need to Be Considered for Triple Therapy, Posters Find
October 16th 2022One poster found patients with uncontrolled asthma had improved outcomes after escalating to triple therapy, while the other found a substantial portion of patients adherent to a dual therapy reported not having controlled asthma.
Read More
Addressing Disparities Starts With Rebuilding Trust, Connecting Better With Patients
October 16th 2022The first 5 minutes of a patient’s visit with a doctor can help improve communication and build more trusting relationships, explained panelists during a session on lung health disparities in America at CHEST 2022.
Read More
Dr Paul Forsberg Highlights the Role of the Reference Product Once Biosimilars Hit the Market
October 16th 2022Biosimilars have had such an impact on driving down costs, that in some instances the reference product might be the lowest cost option, explained Paul Forsberg, PharmD, director of pharmacy, Minnesota Oncology.
Read More
AMA Report Evaluates PBM Competition and Vertical Integration With Insurers
October 14th 2022While a majority of national lives are covered by vertically integrated insurers, the proportion varies widely at the state level from as low as 6% to as high as 97% of covered lives, according to a new American Medical Association (AMA) report about competition in the pharmacy benefit manager (PBM) sector and insurance.
Read More
Glenn Balasky Highlights Continued Value-Based Oncology Care Efforts With Private Payers
October 12th 2022Even though there is a 1-year gap between the Oncology Care Model and the Enhancing Oncology Model, there remain value-based oncology payment programs with private payers, said Glenn Balasky, executive director of Rocky Mountain Cancer Centers.
Read More
ICER to Assess Clinical Effectiveness, Value of 2 NASH Treatments
October 11th 2022There are no FDA-approved therapies for nonalcoholic steatohepatitis (NASH), but there are many being developed. Resmetirom and obeticholic acid are both being reviewed by the FDA with decisions expected in 2023.
Read More
Dr Parisa Emami-Naeni on the Lack of Racial Diversity in Ophthalmology Residency Programs
October 11th 2022Different factors have contributed to the lack of racial diversity in ophthalmology residency programs, and these programs build the future of the workforce, said Parisa Emami-Naeni, MD, MPH, assistant professor of ophthalmology at University of California, Davis, and vitreoretinal surgeon and uveitis specialist at UC Davis Eye Center.
Read More
Considering When to Switch Patients From One Biosimilar to Another
October 9th 2022With more and more biosimilars reaching market, there are considerations around whether to keep patients on their current biosimilar or switch them to another biosimilar as the market dictates, said Paul Forsberg, PharmD, director of pharmacy, Minnesota Oncology.
Read More
Dr Ticiana Leal: A Lot of Work Is Needed Regarding Early Detection in Lung Cancer
October 7th 2022Lung cancer screening rates remain low nationwide, and there is a need to better educate patients and clinicians about the importance of screening, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.
Read More
There Needs to Be an Arbiter of High-Quality, High-Value Cancer Care, Says Dr Lucy Langer
October 6th 2022With multiple pathways and stakeholders involved, there needs to be an arbiter who decides what is the highest quality and highest value care in oncology, said Lucy Langer, MD, MSHS, national medical director, oncology and genomics, UnitedHealthcare.
Read More
High-Dose, Extended Duration Aflibercept Injections Benefit Patients With DME, nAMD
October 3rd 2022Results from the pivotal PHOTON and PULSAR trials highlighted the success of 8-mg aflibercept every 12 or 16 weeks in patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD).
Read More
Dr Ravi Goel Discusses the Future of Technology in Ophthalmic Practice
October 1st 2022The ophthalmology practice of the future will need to manage patients more efficiently and that means incorporating more technology, said Ravi Goel, MD, spokesperson for the AAO and ophthalmologist at Regional Eye Associates in New Jersey.
Read More
Expensive Targeted Lung Cancer Therapies Need to Be Tailored to the Right Patient
September 29th 2022Targeted therapies have improved outcomes for patients with lung cancer, but the goal needs to be tailoring the right therapy to the right patient, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.
Read More
Dr Paul Hahn Highlights Shifting Trends Among Retina Specialists
September 27th 2022There has been a sea change in how retina specialists treat retinal diseases, with a progressive shift toward more utilization of anti–vascular endothelial growth factor (VEGF), said Paul Hahn, MD, vitreoretinal surgeon at NJRetina.
Read More
Dr Grayson Armstrong Highlights How Ophthalmologists Are Early Adopters of Innovation
September 27th 2022Ophthalmology is image heavy, which has made the specialty amenable to telemedicine and the implementation of artificial intelligence, said Grayson Armstrong, MD, medical director, ophthalmic emergency services at Massachusetts Eye and Ear, and instructor in ophthalmology at Harvard Medical School.
Read More